The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
Identifieur interne : 001235 ( PubMed/Corpus ); précédent : 001234; suivant : 001236The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
Auteurs : W. Hugenholtz-Wamsteker ; C. Robbeson ; J. Nijs ; W. Hoelen ; M. MeeusSource :
- European journal of cancer care [ 1365-2354 ] ; 2016.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Taxoids.
- epidemiology : Edema, Lymphedema, Postoperative Complications.
- therapy : Breast Neoplasms.
- Chemotherapy, Adjuvant, Female, Humans, Mastectomy, Risk Factors.
Abstract
Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel-treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.
DOI: 10.1111/ecc.12261
PubMed: 25348689
Links to Exploration step
pubmed:25348689Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.</title><author><name sortKey="Hugenholtz Wamsteker, W" sort="Hugenholtz Wamsteker, W" uniqKey="Hugenholtz Wamsteker W" first="W" last="Hugenholtz-Wamsteker">W. Hugenholtz-Wamsteker</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Robbeson, C" sort="Robbeson, C" uniqKey="Robbeson C" first="C" last="Robbeson">C. Robbeson</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Nijs, J" sort="Nijs, J" uniqKey="Nijs J" first="J" last="Nijs">J. Nijs</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Hoelen, W" sort="Hoelen, W" uniqKey="Hoelen W" first="W" last="Hoelen">W. Hoelen</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Meeus, M" sort="Meeus, M" uniqKey="Meeus M" first="M" last="Meeus">M. Meeus</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:25348689</idno><idno type="pmid">25348689</idno><idno type="doi">10.1111/ecc.12261</idno><idno type="wicri:Area/PubMed/Corpus">001235</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001235</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.</title><author><name sortKey="Hugenholtz Wamsteker, W" sort="Hugenholtz Wamsteker, W" uniqKey="Hugenholtz Wamsteker W" first="W" last="Hugenholtz-Wamsteker">W. Hugenholtz-Wamsteker</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Robbeson, C" sort="Robbeson, C" uniqKey="Robbeson C" first="C" last="Robbeson">C. Robbeson</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Nijs, J" sort="Nijs, J" uniqKey="Nijs J" first="J" last="Nijs">J. Nijs</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Hoelen, W" sort="Hoelen, W" uniqKey="Hoelen W" first="W" last="Hoelen">W. Hoelen</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Meeus, M" sort="Meeus, M" uniqKey="Meeus M" first="M" last="Meeus">M. Meeus</name><affiliation><nlm:affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer care</title><idno type="eISSN">1365-2354</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Breast Neoplasms (therapy)</term><term>Chemotherapy, Adjuvant</term><term>Edema (epidemiology)</term><term>Female</term><term>Humans</term><term>Lymphedema (epidemiology)</term><term>Mastectomy</term><term>Postoperative Complications (epidemiology)</term><term>Risk Factors</term><term>Taxoids (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Edema</term><term>Lymphedema</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Humans</term><term>Mastectomy</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel-treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25348689</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>27</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2354</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of cancer care</Title><ISOAbbreviation>Eur J Cancer Care (Engl)</ISOAbbreviation></Journal><ArticleTitle>The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.</ArticleTitle><Pagination><MedlinePgn>269-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ecc.12261</ELocationID><Abstract><AbstractText>Docetaxel is extensively used in chemotherapy for the treatment of breast cancer. Little attention has been given to oedema as a possible side effect of docetaxel-containing therapies. Until now, no review was conducted to evaluate docetaxel-containing therapies versus docetaxel-free therapies on the magnitude of the risk of developing oedema. In this systematic review, we investigated the risk of developing oedema in patients being treated for breast cancer with or without docetaxel. In this systematic literature review, we searched PubMed and Web of Knowledge for studies on breast cancer patients treated with chemotherapy containing docetaxel. We included clinical trials comparing docetaxel versus docetaxel-free chemotherapy. Oedema had to be reported and measured as a key outcome or an adverse effect. Methodological checklists were used to assess the risk of bias within the selected studies. Seven randomised clinical trials were included. Six trials were of moderate methodological quality. All trials showed an increased rate of oedema in the docetaxel-treatment arm. The trial of weakest methodological quality reported the highest incidence of oedema. The results moderately suggest that adjuvant chemotherapy containing docetaxel is related to a significantly increased risk of developing oedema, compared with docetaxel-free chemotherapy.</AbstractText><CopyrightInformation>© 2014 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hugenholtz-Wamsteker</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Procare Fysiotherapie & Trainingscentrum, Gorinchem, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbeson</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fysiotherapie Heuts, Dinteloord, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nijs</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pain in Motion International Research Group (www.paininmotion.be), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Human Physiology & Physiotherapy, Faculty of Physical Education & Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Physiotherapy, University Hospital Brussels, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoelen</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeus</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>European College for Lymphology & Oncology, De Berekuyl/CSI-the Netherlands, Hierden, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pain in Motion International Research Group (www.paininmotion.be), Brussels, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine & Health Sciences, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer Care (Engl)</MedlineTA><NlmUniqueID>9301979</NlmUniqueID><ISSNLinking>0961-5423</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>15H5577CQD</RegistryNumber><NameOfSubstance UI="C067311">docetaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="Y">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">mamma carcinoma</Keyword><Keyword MajorTopicYN="N">risk</Keyword><Keyword MajorTopicYN="N">taxotere</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25348689</ArticleId><ArticleId IdType="doi">10.1111/ecc.12261</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001235 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001235 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25348689
|texte= The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25348689" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |